Biofrontera AG - shares for investment in kind agreement registered

Biofrontera AG / Biofrontera AG - shares for investment in kind agreement registered . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. Leverkusen, Germany - Biofrontera AG (hereafter called Biofrontera) had announced on 15 June, 2011, that on this day she had signed an agreement with ASAT Applied Science and Technology AG, Zug, Switzerland (hereafter called "ASAT"), according to which a debt claim against Biofrontera Bioscience GmbH (a wholly owned subsidiary of Biofrontera) was transferred to Biofrontera against new Biofrontera shares. In return to passing the debt claim of about € 2.094 mln. to Biofrontera, ASAT was to receive 385,000 new Biofrontera name shares. In the meantime, a certified appraisal was issued, upon which yesterday the capital increase was registered. Biofrontera's equity capital now amounts to € 11,240,486.00, divided into 11,240,486 shares. The herewith lapsed claims of ASAT stemmed from 2004, when Biofrontera purchased know-how and patents related to her leading product BF-200 ALA, which is currently in the European approval process. The debt transfer of € 2.094 mln. in exchange for 385,000 shares relates to a calculative share price of € 5.44. ASAT has agreed to a one-year lock-up period following the registration of the shares. Background BF-200 ALA gel is a drug for the treatment of actinic keratosis. It is applied in the relatively novel photodynamic therapy (PDT). This therapy is a one-time treatment of actinic keratosis lesions with very high efficacy and excellent cosmetic results, without the side-effects and discomfort of a long-term treatment. Actinic keratosis is a superficial skin cancer that is still restricted to the upper skin layer (the epidermis). These tumors result from UV-light induced lesions accumulating during the life time. They occur very frequently in sun- exposed skin regions. In about 10-15% of the affected people the actinic keratosis lesions develop into malignant, potentially fatal squamous cell carcinomas. About Biofrontera AG Biofrontera aims at attending and treating the skin, recognizing the aesthetic needs of a person's visual reflection. Biofrontera is listed in the regulated market of the Düsseldorf stock exchange under the symbol B8F and the ISIN number DE0006046113. www.biofrontera.com For further information please contact: Werner Pehlemann CFO + 49 (0) 214 87632 0 + 49 (0) 214 87632 90 w.pehlemann@biofrontera.com Biofrontera AG Hemmelrather Weg 201 D- 51377 Leverkusen, Germany --- End of Message --- Biofrontera AG Hemmelrather Weg 201 Leverkusen Germany WKN: 604611;ISIN: DE0006046113; Listed: Freiverkehr in Börse Stuttgart, Freiverkehr in Börse Berlin, Open Market (Freiverkehr) in Frankfurter Wertpapierbörse, Freiverkehr in Bayerische Börse München, Regulierter Markt in Börse Düsseldorf; This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Biofrontera AG via Thomson Reuters ONE [HUG#1542498]